

Paris, 26 June 2019

## Press release

### License signed with the start-up, Orixha for developing an ultra-fast, therapeutic, hypothermia system, using liquid ventilation in cases of cardiac arrest



*Monday, 17 June 2019, Erganeo and the start-up Orixha signed an exclusive worldwide license for the use of an innovative liquid ventilation technology, inducing ultra-fast therapeutic hypothermia in the vital organs of patients suffering from cardiac arrest. This win-win relationship shows Erganeo's strengthened commitment to its start-ups.*

#### **A breakthrough technology meeting a critical medical need**

Each year, 7 million people in the world, die from out-of-hospital cardiac arrest. After 15 years of work, research teams led by Prof. Renaud Tissier (INSERM, EnvA, Institut Mondor) and Prof. Philippe Micheau (Université de Sherbrooke, Canada) have developed a safe and sophisticated technology to reduce this mortality through the beneficial effects of ultra-fast hypothermia. This technology uses the lungs as heat exchangers by ventilation of a breathable liquid at a controlled temperature. Gas exchange is ensured, and the induced hypothermia protects the brain, heart, and other vital organs (kidneys and liver) from reperfusion injury.

#### **Birth of a start-up: Orixha Medical**

This innovative technology is being used by the start-up, Orixha, to develop an ultra-fast, therapeutic hypothermia system that improves the vital prognosis in cases of cardiac arrest. With solid preclinical proof of concept, Orixha is aiming for market authorisation within 3 to 4 years, once clinical human trials have been conducted. Its CEO Fabrice Paublant has the support of his co-founders' expertise and the results obtained by the academic laboratories where the technology originated.

#### **Erganeo's strong commitment**

Erganeo identified this project and provides financial support and patent application

management, building on the upstream work by TransferTech Sherbrooke. It strengthened its commitment, on 17 June 2019, with the signing of the license. *“Erganeo is also playing a role, by investing in Orixha, and participating in its monitoring committee, which demonstrates our strong support for the growth of the start-ups we help create”,* stated Suat Topsu, CEO of Erganeo.

*“Erganeo and the supervisory authorities enabled researchers on both sides of the Atlantic to develop this technology, a first worldwide, while securing the intellectual property. We are delighted this license has been signed and that Erganeo has invested in Orixha. This shows an alignment of interests among all parties to transform this innovation into a medical system that will improve the survival rate in cases of cardiac arrest,”* noted Fabrice Paublant, CEO of Orixha.

## **About Erganeo** – [www.erganeo.com](http://www.erganeo.com)

Erganeo is a French investment firm, specialized in breakthrough innovations (DeepTech) with strong societal impact. We invest as early as possible to secure new inventions by researchers, upstream of their transfer to an industry partner or the creation of a start-up. We work in several scientific fields: Biotech, Infotech (Telecoms, internet of things, big data, AI), Energy technology (new energies, chemistry, materials), etc.

Our mission is to accelerate and simplify relations between research and industry, promoting societal progress. To this end, we finance and support the success and international recognition of the new generation of French researchers-entrepreneurs.

A member of the SATT network, Erganeo draws on the Paris region ecosystem to lay the foundations for a better future. This rich, innovative environment includes 20,000 researchers in more than 370 high-tech research laboratories. Since its creation, Erganeo has invested more than €27 M, contributing to 67 new licenses with companies of all sizes and 14 new start-ups.

Press contact: Céline Clausener – Director of public relations – [celine.clausener@erganeo.com](mailto:celine.clausener@erganeo.com)

## **About Orixha** - [www.orixha.com](http://www.orixha.com)

CEO: Fabrice Paublant

Research team: Renaud Tissier, Alain Berdeaux, Matthias Kohlhauer, Hervé Walti, Mathieu Nadeau, Philippe Micheau  
Orixha is developing the LV4C medical system (Liquid Ventilation for Cooling) for near-immediate protection of vital organs (brain, heart, liver, kidneys) from reperfusion injury following cardiac arrest. In this way, LV4C makes it possible to reduce mortality and morbidity in post cardiac arrest syndrome.

Contact: Fabrice Paublant – CEO [paublant@orixha.com](mailto:paublant@orixha.com)